CANCER DIAGNOSTICS RESEARCH

assay

Studies to Determine Cancer Aggressiveness

The blood test can also provide information that helps determine the aggressiveness of the cancer independent of imaging. The analysis is based on cancer associated cells.

The features indicating aggressive cancers are listed below.  The features are independent of type of cancer or stage.

Publications

Major Features Suggestive of Poor Prognosis:

The presence of the following features suggest poor PFS and OS independent of the type of cancer or stage.

  • CTC number > 5
  • CTC in mitosis
  • CAML size ≥ 50 µm
  • Micronuclei (MN) in CAMLs
  • Extracellular Vesicles (EVs) budding from CAMLs
  • Debris in CAMLs
  • Micronuclei (MN) in CAMLs
  • DAPI size of CAMLs >465 µm2
  • CTC clusters
  • Presence of other types of tumor-macrophage hybrid cells (TMHCs) besides CAMLs

CAMLs contains tumor markers and are ideal for companion diagnostics because they are found in all cancers and all stages of cancer.

Creatv Bio has developed more than 30 drug targets including:

  • PD-L1, PD-L2

  • HER2

  • CCR5

  • CXCR4

  • VEGFR1-2

Research on Companion/Complementary Diagnostics

Many cancer drugs target specific markers on the surface of the tumor.  If the tumor does not express the marker, studies suggest that it is not expected to respond to the drug. The test to determine effective use of the therapeutic drug for a patient is called companion diagnostics.

A simple blood test can be developed for companion diagnostics for the drug, which is simpler and cheaper than tissue biopsy.

Publications